Baxter International Inc. logo
Baxter International Inc. (BAX)
Compare

BAX Dividends

Baxter International Inc. (BAX) pays $0.20 in dividends per share, with a current dividend yield of 0.98%.

BAX Dividend Summary

Consecutive Years

0

Most Recent Ex-Date

May 29, 2026

Next Payment Date

Jul 1, 2026

BAX Dividends per Share (Nominal History)

View full nominal table list

This step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.

BAX Dividends CAGR Chart

Baxter International Inc. (BAX)

Annual Dividend History

YearDividend/ShareYoY Growth
2026(YTD)$0.02
2025$0.52-50.00%
2024$1.04-10.34%
2023$1.16+0.87%
2022$1.15+5.99%
2021$1.08+13.61%
2020$0.95+12.35%
2019$0.85+16.44%
2018$0.73+19.67%
2017$0.61+20.79%
2016$0.51-36.47%
2015$0.79-28.61%
2014$1.11+6.77%
2013$1.04+22.29%
2012$0.85+24.11%
2011$0.69+7.21%
2010$0.64+10.28%
2009$0.58+17.07%
2008$0.50+26.59%
2007$0.39N/A

Quarterly Dividend History

QuarterDividend/ShareYoY Growth
Q2 2026$0.01-94.12%
Q1 2026$0.01-94.12%
Q4 2025$0.01-94.12%
Q3 2025$0.17-41.38%
Q2 2025$0.17-41.38%
Q1 2025$0.17-41.38%
Q4 2024$0.17-41.38%
Q3 2024$0.29+0.00%
Q2 2024$0.29+0.00%
Q1 2024$0.29+0.00%
Q4 2023$0.29+0.00%
Q3 2023$0.29+0.00%
Q2 2023$0.29+0.00%
Q1 2023$0.29+3.57%
Q4 2022$0.29+3.57%
Q3 2022$0.29+3.57%
Q2 2022$0.29+3.57%
Q1 2022$0.28+14.29%
Q4 2021$0.28+14.29%
Q3 2021$0.28+14.29%
Q2 2021$0.28+14.29%
Q1 2021$0.24+11.36%
Q4 2020$0.24+11.36%
Q3 2020$0.24+11.36%

Dividend Yield Metrics

Current Yield
0.98%
Average Yield (TTM)
0.98%
Average Yield (3Y)
4.46%
Forward Yield on Cost (3Y)
0.47%
Forward Yield on Cost (5Y)
0.29%
Forward Yield on Cost (10Y)
0.08%

Payout Ratio Analysis

Payout Ratio (Current)
N/A
FCF Payout Ratio
14.37%
Payout Ratio (3Y Avg)
36.16%
Payout Ratio (5Y Avg)
35.13%
FCF Payout (3Y Avg)
74.32%
FCF Payout (5Y Avg)
71.83%

Dividend Coverage

Payout Ratio
N/A
Dividends / net income
FCF Payout Ratio
14.4%
Dividends / free cash flow
Consecutive Years
N/A
Years with regular dividend payments
5Y Dividend Growth
-11.4%
Compound annual dividend growth

About Baxter International Inc.

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Deerfield, IL
38,000 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Andrew Hider